摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-difluoro-2-(2,2,2-trifluoro-ethoxy)-benzonitrile | 870063-11-9

中文名称
——
中文别名
——
英文名称
4,5-difluoro-2-(2,2,2-trifluoro-ethoxy)-benzonitrile
英文别名
4,5-Difluoro-2-(2,2,2-trifluoroethoxy)benzonitrile
4,5-difluoro-2-(2,2,2-trifluoro-ethoxy)-benzonitrile化学式
CAS
870063-11-9
化学式
C9H4F5NO
mdl
——
分子量
237.129
InChiKey
PKKVYCPRSCVFPB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    33
  • 氢给体数:
    0
  • 氢受体数:
    7

文献信息

  • [EN] AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE<br/>[FR] ANALOGUES D'AMINO-TÉTRAZOLES ET MÉTHODES D'UTILISATION
    申请人:ABBOTT LAB
    公开号:WO2005111003A1
    公开(公告)日:2005-11-24
    A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.
    公开了具有化学式(I)或化学式(II)的化合物作为P2X7拮抗剂,其中A、B、C、Y、Y、Z、m、v、R1、R2、R3、R4和R5如描述中所定义。还公开了用于治疗受P2X7调节的疾病或症状的方法和组合物。
  • Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals
    申请人:Keil Stefanie
    公开号:US20080261979A1
    公开(公告)日:2008-10-23
    The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator receptor (PPARdelta) agonist activity. The compounds of the present invention are comprised of the formula: wherein the substituents R1-R5 and R7-R10 are defined herein. The compounds are therapeutically effective in the regulation and modulation of lipid and carbohydrate metabolism in mammals and are thus suitable for the treatment of diseases such as type-2 diabetes, atherosclerosis, cardiovascular disorders and the like.
    本发明的创新化合物由苯基和吡啶基-1,2,4-噁二唑酮生物以及它们的生理上可接受的盐和功能衍生物组成,已被证明具有过氧化物酶体增殖激活受体(PPARδ)激动剂活性。本发明的化合物由以下公式组成:其中取代基R1-R5和R7-R10在此定义。这些化合物在哺乳动物的脂质和碳水化合物代谢的调节和调控方面具有治疗效果,因此适用于治疗糖尿病、动脉粥样硬化、心血管疾病等疾病。
  • Amino-tetrazole analogues and methods of use
    申请人:Carroll A. William
    公开号:US20060052374A1
    公开(公告)日:2006-03-09
    A compound having Formula (I) or Formula (II) is disclosed as an P2X 7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R 1 , R 2 , R 3 , R 4 , and R 5 , are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X 7 are also disclosed.
    本文披露一种化合物,其化学式为(I)或(II),作为P2X7拮抗剂,其中A、B、C、Y、Y、Z、m、v、R1、R2、R3、R4和R5如描述中所定义。同时,本文还披露了治疗P2X7调节的疾病或病症的方法和组合物。
  • Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof
    申请人:Keil Stefanie
    公开号:US20080262036A1
    公开(公告)日:2008-10-23
    The present invention comprises phenyl-[1,2,4]-oxadiazol-5-one derivatives of the general formula I: wherein the R1-R10 and B, U, V, W, X, Y and Z substituents are defined herein. The claimed invention also comprises the compounds isomers and their physiologically acceptable salts as well as processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    本发明涉及一般式I的苯基-[1,2,4]-噁二唑-5-酮衍生物,其中R1-R10和B、U、V、W、X、Y和Z取代基在此定义。所述发明还包括所述化合物的异构体及其生理上可接受的盐,以及它们的制备方法。所述化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍,以及胰岛素抵抗涉及的障碍以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病的治疗。
  • PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    申请人:Bernardelli Patrick
    公开号:US20090281084A1
    公开(公告)日:2009-11-12
    The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    本发明涉及具有苯基的苯基-1,2,4-噁二唑酮生物及其生理上可接受的盐和生理上功能衍生物,显示PPARδ激动剂活性。所描述的是式I的化合物,其中基团如定义所述,以及它们的生理上可接受的盐和它们的制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的障碍以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯